Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5427]

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised...

Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer ( Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK )

Updates on metastatic bladder cancer from ASCO GU 2019

Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA

Updates on metastatic bladder cancer from ASCO GU 2019 ( Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA )

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell...

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

$Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )$

Sacituzumab govitecan in patients with previously treated metastatic urothelial...

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Dr Arjun Balar - NYU Langone Health, New York City, USA

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ( Dr Arjun Balar - NYU Langone Health, New York City, USA )

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line...

Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC ( Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy )

BGICC 2019 ( )

Positive feedback of clinical trials, research and patient outcomes

Prof Carlos Barrios - Pontifica Universidade Catolica de Rio Grande do Sul...

Positive feedback of clinical trials, research and patient outcomes ( Prof Carlos Barrios - Pontifica Universidade Catolica de Rio Grande do Sul, Porto Alegre, Brazil )

When to increase and decrease burden of treatment for breast cancer patients

Prof Pierre Conte - Istituto Oncologico Veneto, Padova, Italy

When to increase and decrease burden of treatment for breast cancer patients ( Prof Pierre Conte - Istituto Oncologico Veneto, Padova, Italy )

More from ecancer